Updated : April 2025

Abacavir (sulfate)/lamivudine 120mg/60mg dispersible tablets (Micro Labs Ltd), HA763

LABELLING

WHOPAR Part 5 Updated: April 2025

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING **HDPE** bottle

1. Name of the medicinal product

[HA763 trade name]* Abacavir (as sulfate) /Lamivudine 120 mg /60 mg Dispersible Tablets

2. Statement of active substance

Each dispersible tablet contains 120 mg abacavir (as sulfate) and 60 mg lamivudine.

3. List of excipients

(Micro Labs Ltd), HA763

4. Pharmaceutical form and contents

Dispersible tablets

30 tablets

60 tablets

5. Method and route of administration

Oral use.

Read the patient information leaflet before use.

6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep this medicine out of the sight and reach of children.

7. Other special warning(s), if necessary

8. Expiry date

EXP {MM/YYYY}

9. Special storage conditions

Do not store above 30°C. Store in the original container.

10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate

11. Name and address of the supplier

Micro Labs Limited

#31, Race Course Road,

Bangalore - 560001, Karnataka, India.

12. WHO Reference Number (Prequalification Programme)

HA763

13. Manufacturer's batch number

<Batch> <Lot> {number}

14. (Advice on) General classification for supply

Medicinal product subject to medical prescription.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility. Page 2 of 3

Updated : April 2025

15. Instructions on use